Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced or Metastatic Renal Cell Carcinoma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 150

Sponsor: Ipsen

Location: Onze-Lieve-vrouw Ziekenhuis Aalst Aalst

Summary

The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)

Eligibility Criteria

Inclusion Criteria: * Males or females aged 18 years and older * Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or metastatic renal cell carcinoma * Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study * Provision of written informed consent Exclusion Criteria: * Participation in another interventional clinical study at the same time * Previous participation in this clinical study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04106349). StuddyBuddy aggregates publicly available trial information.